Search Contact
This page is available in multiple languages
Select Language

Inify Laboratories lists on Euronext Growth Oslo

Back

  • The sixth listing on Euronext Growth Oslo in 2022
  • Market capitalisation of approximately NOK 181 million

 

Oslo – 20 June 2022 – Oslo Børs, part of the Euronext Group, today congratulate Inify Laboratories AB (ticker: INIFY) on their listing on Euronext Growth Oslo. This is the sixth listing on Euronext Growth Oslo so far in 2022.  

Inify Laboratories is a Swedish company providing cancer diagnostics through ultra-modern laboratory services within pathology. It uses a fully digital, standardized and AI-supported workflow to optimize quality and response times, initially within prostate cancer. The company is currently building an ultra-modern laboratory located at Solna, Sweden. The company is a spin-off from the Oslo Børs listed MedTech company ContextVision.

At opening, the share price was set at NOK 4, corresponding to a total estimated value of NOK 181 million  

Fredrik Palm, CEO of Inify Laboratories said: “I’m truly thrilled to announce that Inify Laboratories is admitted to trading on Euronext Growth Oslo, less than 5 months after we became independent. With solid funding of NOK 150 million, provided through an equity issue towards supportive long-term shareholders as well as the management and Board of Directors, we have all prerequisites in place to develop the company and create a monumental paradigm shift within cancer diagnostics. The concept is scalable in terms of volume, diagnoses and geographical expansion which enable us to advance fast and create value for patients and clinicians. We offer a unique, attractive workplace for our multidisciplinary team where we merge technical and medical expertise in the same organization, sharing our vision to deliver world-leading cancer diagnostics.”

 

About Inify Laboratories AB

Inify Laboratories provides cancer diagnostics through ultra-modern laboratory services within histopathology. Fully digital, standardized and AI- supported workflow is applied to optimize quality and response times, initially for prostate cancer. The concept is scalable and extendible to other diagnosis. The company origins from ContextVision and became independent in February 2022. The company is based in Sweden and listed on Euronext Growth Oslo under the ticker INIFY.

Download press release - Inify Laboratories

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With nearly 1,900 listed issuers and around €6.3 trillion in market capitalisation as of end September 2024, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2024, Euronext N.V. - All rights reserved.